Linezolid Hikma

Linezolid, the active ingredient in Linezolid Hikma, is an oxazolidinone antibiotic presented as an intravenous solution for injection use. It treats serious bacterial infections, including complicated skin and soft‑tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by MRSA or VRE, in adult patients.

GNH USA supplies Linezolid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable supply chains and responsive technical support.

Linezolid is an oxazolidinone antibiotic used to treat infections caused by Gram‑positive bacteria.

- Complicated skin and soft tissue infections: effective therapy for adult patients with infections caused by susceptible Gram‑positive organisms. - Community‑acquired bacterial pneumonia: provides bacterial clearance in patients with pneumonia due to susceptible pathogens. - Nosocomial pneumonia: used for hospital‑acquired lung infections when other agents are unsuitable. - MRSA and VRE infections: offers an option for resistant Gram‑positive infections where alternatives may be limited.

Linezolid may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Anemia: reduced red blood cell levels. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Severe hepatic injury: potential liver enzyme elevation.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

- Renal impairment: adjust therapy based on renal function and monitor for accumulation. - Hepatic impairment: monitor liver enzymes regularly during treatment. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Myelosuppression: perform complete blood‑count monitoring to detect thrombocytopenia or anemia. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Linezolid can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): increased risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome. - Rifampin: reduces linezolid plasma concentrations, compromising efficacy. - Tyramine‑rich foods: may elevate blood pressure when combined. - Serotonergic opioids (e.g., tramadol): heightened serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Cytochrome P450 inducers (e.g., carbamazepine): may lower linezolid exposure, requiring efficacy assessment.